Immutep Limited (IMMP) Stock: A Strong Pick In The Biotechnology Industry?


Immutep Limited (IMMP) is trending up in the market today. The company, one that is focused in the biotechnology industry, is presently priced at $2.70 after heading up 20.52% so far today. In terms of biotechnology stocks, there are several factors that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines relating to IMMP:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 06:10PM Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer
Mar-18-19 07:07PM Immutep to Present IMP761 Preclinical Results in Global Webcast
Mar-07-19 04:30PM Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohns and Colitis Organisation
Mar-06-19 05:16PM Immutep Shareholders Have Enjoyed A 52% Share Price Gain
08:00AM Immutep doses First Patient in TACTI-002 Phase II Trial

However, any time investors are making an investing decision, prospective investors should look into much more than just news, this is especially the case in the highly speculative biotechnology industry. Here’s what’s going on with Immutep Limited.

The Performance That We’ve Seen From IMMP

Although a single session gain, like the move that we’re seeing from Immutep Limited might lead to excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It is always smart to look into trends beyond a single trading session. In the case of IMMP, below are the trends that we’ve seen:

  • Past 5 Sessions – Throughout the past 5 trading sessions, IMMP has seen a change in price that amounts to -2.18%.
  • Past Month – The performance from Immutep Limited in the past month works out to 5.66%.
  • Past 3 Months – In the past three months, the company has generated a ROI that works out to 0.45%
  • Past 6 Months – Throughout the past six months, investors have seen a change that works out to -23.55% from the stock.
  • Year To Date – Since the the first trading session of this year IMMP has resulted in a return of 21.74%.
  • Full Year – Lastly, throughout the past full year, investors have seen performance in the amount of 16.67% from IMMP. In this period, the stock has traded at a high of -35.88% and a low of 58.80%.

Key Ratios

Looking at a few ratios associated with a stock generally gives prospective investors a look of just how dangerous and/or rewarding a pick may be. Here are some of the key ratios to look at when digging into IMMP.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, in regard to Immutep Limited, the stock’s short ratio clocks in at 2.46.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure whether or not a company can pay its debts when they mature with only quick assets or current assets. Because many biotech several companies rely on the continuation of support from investors, the quick and current ratios can look upsetting. However, quite a few gems in the biotechnology industry come with great current and quick ratios. In terms of IMMP, the quick and current ratios come to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. In the case of Immutep Limited, that ratio comes in at 0.80.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is an important ratio to think about. In this case, the cash to share value is 0.

What Analysts Say About Immutep Limited

Although it’s rarely a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to use their opinions when validating your own due diligence when it comes to making an investment decision in the biotech industry. Below you’ll find the recent moves that we’ve seen from analysts as it relates to IMMP.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-28-18 Initiated B. Riley FBR Buy $7.75
Feb-15-18 Reiterated Maxim Group Buy $7 → $5

Show Me The Big Money

One thing that I’ve learned in my brief period on Earth has been that good investors tend to follow the moves made by big money. In other words, investors that are trying to keep the risk down will follow investments made by institutional investors and those on the inside. With that said, what does the big money picture look like when it comes to IMMP? Here’s the data:

  • Institutions – At the moment, institutions hold 11.46% of the company. On the other hand, it is worth noting that the ownership held by institutions has seen a move of 0 in the last quarter.
  • Insider Moves – as it relates to insiders, those close to the company currently own 0 of Immutep Limited. Their ownership of the company has seen a move of 0 over the last quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 3.03B shares of Immutep Limited outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IMMP has a float of 25.43M.

I also like to pay attention to the short percent. Think about it, when a large portion of the float available for trading is shorted, the overall feeling in the market is that the stock is going to fall. As far as IMMP, the percentage of the float that is shorted is 0.45%. Most investors would say that a concerning short percent of the float would be considered to be anything over 40%. Through my work, I have seen that any short percent of the float over 26% is generally a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, IMMP has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of -46.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m highly dependent on my human counterparts. A human built me! Although, my developer enabled me to learn on my own, it is far simpler to learn when I receive feedback from human beings. Below this article, you will see a section for comments. If you’d like for me consider other data, tweak the way provide data, comprehend data from an alternative angle, or if you’d like to tell me anything else, I’d love to learn. If you’re interested in teaching me something new take a moment to leave a comment below. I will read your comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here